Trials / Completed
CompletedNCT00191568
Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer
A Phase II Trial of Adjuvant Treatment With Gemcitabine and Oxaliplatin Followed by Concomitant Gemcitabine and Radiation Therapy in Patients With Resected Pancreatic Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A non-randomized phase II study to determine the efficacy and safety of the combination of Gemcitabine and Oxaliplatin followed by Gemcitabine and radiotherapy in patients with surgically resected pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine | |
| DRUG | Oxaliplatin | |
| PROCEDURE | Radiotherapy |
Timeline
- Start date
- 2002-10-01
- Completion
- 2007-05-01
- First posted
- 2005-09-19
- Last updated
- 2007-10-19
Locations
6 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00191568. Inclusion in this directory is not an endorsement.